Gregory W. Daniel

vaccination003_16x9

Vaccines and nervous parents: Why spacing out the vaccine schedule is not the answer

Gregory W. Daniel, Elizabeth Richardson, and Heather Colvin

Monday, October 26, 2015

health_care021_16x9

Incorporating continuing education into single-drug REMS: Exploring the challenges and opportunities

Gregory W. Daniel and Mark B. McClellan

Wednesday, May 20, 2015

health360_pharma1

Event recap: Lessons learned from two years of breakthrough therapy designation

Gregory W. Daniel, Elizabeth Richardson, and Craig Streit

Thursday, May 14, 2015

iStock_000006057413Small

Why legislative proposals to improve drug and device development must look beyond FDA approvals

Gregory W. Daniel, Morgan Romine, and Mark B. McClellan

Tuesday, April 28, 2015

RTR1WOB4

Faster, more efficient innovation through better evidence on real-world safety and effectiveness

Mark B. McClellan, Gregory W. Daniel, Adam Aten, Heather M. Colvin, and Morgan H. Romine

Tuesday, April 28, 2015

health_meddevice

The medical device tax: A primer

Gregory W. Daniel

Thursday, April 23, 2015

RTR3IICV

Breakthrough therapy designation: A primer

Gregory W. Daniel, Elizabeth Richardson, and Craig Streit

Tuesday, April 21, 2015

health_exchange_website002

Cost, value and patient outcomes: The growing need for payer engagement

Gregory W. Daniel and Morgan H. Romine

Monday, April 20, 2015

ucla

Advancing antibiotic development in the age of ‘superbugs’

Gregory W. Daniel

Friday, February 27, 2015

Restarting antibiotic innovation

Gregory W. Daniel

Thursday, February 26, 2015